Armata Pharmaceuticals (ARMP) Share-based Compensation (2013 - 2026)

Armata Pharmaceuticals has disclosed Share-based Compensation across 14 years of filings, most recently posting $1.1 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.1 million, up 37.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (down 7.52% YoY), and the FY2025 annual result was $2.6 million, down 9.78% from the prior year.
• Share-based Compensation came in at $1.1 million for Q1 2026 at Armata Pharmaceuticals, up from $632000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.3 million in Q2 2024 to a low of -$373000.0 in Q3 2023.
• The 5-year median for Share-based Compensation is $632000.0 (2025), against an average of $624764.7.
• Across the five-year window, Share-based Compensation tumbled 144.09% in 2023 and surged 411.49% in 2024, its largest moves.
• Armata Pharmaceuticals' Share-based Compensation stood at $817000.0 in 2022, then tumbled by 76.38% to $193000.0 in 2023, then jumped by 83.42% to $354000.0 in 2024, then jumped by 78.53% to $632000.0 in 2025, then soared by 70.09% to $1.1 million in 2026.
• The last three Share-based Compensation figures came in at $1.1 million (Q1 2026), $632000.0 (Q4 2025), and $622000.0 (Q3 2025), per Business Quant data.